Advertisement

The Role of the Epidermal Growth Factor Receptor in Breast Cancer

  • Samuel K. Chan
  • Mark E. Hill
  • William J. GullickEmail author
Article

Abstract

Recent trials of drug therapy targeting the erbB receptor HER2 have met with success in breast cancer. The epidermal growth factor receptor or EGFR is a closely related receptor from this same family that is involved in cellular signal transduction and tumor cell growth and survival. Emerging evidence indicates that EGFR is implicated in the development of hormone-resistant breast cancer, and that its activity is intertwined with estrogen receptor. Here, the role of EGFR in breast cancer is reviewed, and data from selected clinical trials of signal transduction inhibition of this cellular target are summarized.

Keywords

Breast ErbB EGFR Signal transduction Hormone resistance Gefitinib Erlotinib 

Abbreviations

HER

human epidermal growth factor receptor

EGFR

epidermal growth factor receptor

ER

estrogen receptor

PR

progesterone receptor

pMAPK

phosphorylated mitogen activated protein kinase

EGFRvIII

type 3 variant of EGFR

ATP

adenosine triphosphate

IGF1-R

insulin growth factor 1 receptor

References

  1. 1.
    Gullick WJ. The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer 2001;8(2):75–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Carpenter G, King L, Jr., Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 1978;276(5686):409–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005;12 Suppl 1:S17–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003;284(1):2–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284(1):31–53.PubMedCrossRefGoogle Scholar
  6. 6.
    Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich, A. Schlessinger J, Waterfield MD. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307(5951):521–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284(1):99–110.PubMedCrossRefGoogle Scholar
  8. 8.
    Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Mendelson J. Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000;6(3):747–53.Google Scholar
  10. 10.
    Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2001;2(3):4–11.Google Scholar
  11. 11.
    Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol 2004;315 Suppl 10:6–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005;12(3):243–53.PubMedGoogle Scholar
  13. 13.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13(1):3–17.PubMedCrossRefGoogle Scholar
  16. 16.
    Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29(1):41–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, Namer M, Milano G. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 2001;12(6):841–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Robertson JF, Ellis IO. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin Cancer Res 2004;10(7):2578.PubMedGoogle Scholar
  19. 19.
    Ueda S, Tsuda H, Sato K, Takeuchi H, Shigekawa T, Mochizuki H. Differential overexpressions of EGFR, c-erbB-2, and IGF1R in histological types, nuclear grades, and hormone receptors status of breast carcinoma. Abstract 5114. In: San Antonio Breast Cancer Symposium; 2005.Google Scholar
  20. 20.
    Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO. Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol 2005;12(5):271–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002;8(11):3454–60.PubMedGoogle Scholar
  22. 22.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177–82.PubMedCrossRefGoogle Scholar
  23. 23.
    Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R. Best practice no 176: updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57(3):233–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Bloom K. The distribution of EGFR mRNA expression in 247 breast carcinomas and its relationship to ER mRNA expression. Abstract 3039. In: San Antonio Breast Cancer Symposium; 2005.Google Scholar
  25. 25.
    Nicholson RI, Johnston SR. Endocrine therapy—current benefits and limitations. Breast Cancer Res Treat 2005;93 Suppl 1:S3–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 2005;56 Suppl 1:10–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2005:1–16.Google Scholar
  28. 28.
    Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003;17(3):309–17.PubMedCrossRefGoogle Scholar
  29. 29.
    McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001;142(7):2776–88.PubMedCrossRefGoogle Scholar
  30. 30.
    Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144(3):1032–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004;10 1 Pt 2:346S–54S.PubMedCrossRefGoogle Scholar
  32. 32.
    Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001;95(4):247–54.PubMedCrossRefGoogle Scholar
  33. 33.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000;406(6797):747–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353(19):2012–24.PubMedCrossRefGoogle Scholar
  35. 35.
    Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer—search and destroy. Eur J Cancer 2006;42(1):17–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim KH, Lee JY, Yoo NJ, Lee SH. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12(1):57–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Konecny G, Finn F, Seshagiri S, DeForge L, Untch M, Wang H, Kahlert S, Slamon DJ, Pegram MD. Evaluation of TGF-expression and prevalence of EGFR and HER2 kinase domain mutations in breast cancer. In: San Antonio Breast Cancer Symposium, abstract 3029; 2005.Google Scholar
  38. 38.
    Rae JM, Scheys JO, Clark KM, Chadwick RB, Kiefer MC, Lippman ME. EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat 2004;87(1):87–95.PubMedCrossRefGoogle Scholar
  39. 39.
    Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells. Oncogene 1996;13(2):275–82.PubMedGoogle Scholar
  40. 40.
    Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62(20):5749–54.PubMedGoogle Scholar
  41. 41.
    Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19(13):3267–79.PubMedGoogle Scholar
  42. 42.
    Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30(3):255–68.PubMedCrossRefGoogle Scholar
  43. 43.
    Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7(4):301–11.PubMedCrossRefGoogle Scholar
  44. 44.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6(5):2053–63.PubMedGoogle Scholar
  45. 45.
    Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 2002;963:104–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96(12):926–35.PubMedCrossRefGoogle Scholar
  47. 47.
    Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11(4):793–814.PubMedCrossRefGoogle Scholar
  48. 48.
    Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004;90(1):236–44.PubMedCrossRefGoogle Scholar
  49. 49.
    Staka CM, Nicholson RI, Gee JM. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer 2005;12 Suppl 1:S85–97.PubMedCrossRefGoogle Scholar
  50. 50.
    Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005;7(4):R570–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004;3(9):1119–25.PubMedGoogle Scholar
  52. 52.
    Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 2002;98(3):463–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351(4):337–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13(1):65–72.PubMedCrossRefGoogle Scholar
  55. 55.
    Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 2004;10(7):2512–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8(10):3250–8.PubMedGoogle Scholar
  57. 57.
    Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23(23):5323–33.PubMedCrossRefGoogle Scholar
  58. 58.
    von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, Schneeweiss A. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;89(2):165–72.CrossRefGoogle Scholar
  59. 59.
    Albain K ER, Gradishar WJ, et al. Open-label, phase II, multicenter trial of ZD 1839 (‘Iressa’) in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76(S33(suppl 1; abstr 20)).Google Scholar
  60. 60.
    Francis P, Green M, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Forbes J. Gefitinib has a low clinical benefit rate in advanced breast cancer patients. In: San Antonio Breast Cancer Symposium. Abstract 4080; 2005.Google Scholar
  61. 61.
    Robertson J, Gutteridge E, Cheung K, Owers R, Koehler M, Hamilton L, Gee J, Nicholson RI. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Abstract No: 23. In: Proc Am Soc Clin Oncol 22: page 7, 2003 (abstr 23).Google Scholar
  62. 62.
    ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clin Adv Hematol Oncol 2003;1(4):237.Google Scholar
  63. 63.
    Mita M, de Bono J, Mita A, Patnaik A, Ricart A, Berg K, Takimoto C, Rowinsky EK, Tolcher A, Beeram M. A phase II and biologic correlative study investigating anastrozole (A) in combination with geftinib (G) in post menopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy. In: San Antonio Breast Cancer Symposium. Abstract 1117; 2005.Google Scholar
  64. 64.
    Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005;6(6):383–91.PubMedCrossRefGoogle Scholar
  65. 65.
    Ciardiello F, Troiani T, Caputo F, de Laurentiis M, G. Tortora G, G. Palmieri G, de Vita F, Colantuoni G, de Placido S, Bianco A. Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer. Abstract No: 3080. In: 2005 ASCO Annual Meeting.Google Scholar
  66. 66.
    Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 2005;92(1):1–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22(5):785–94.PubMedCrossRefGoogle Scholar
  68. 68.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol 2004;22(5):777–84.PubMedCrossRefGoogle Scholar
  69. 69.
    Kim TE, Murren JR. Erlotinib OSI/Roche/Genentech. Curr Opin Investig Drugs 2002;3(9):1385–95.PubMedGoogle Scholar
  70. 70.
    Graham D, Hillman D, Hobday T, Rousey S, Nair S, Soori G, Sabagh TM, Perez EA. N0234: phase II study of erlotinib (OSI-774) plus gemcitabine as first- or second-line therapy for metastatic breast cancer (MBC). Abstract No. 644. In: 2005 ASCO Annual Meeting.Google Scholar
  71. 71.
    Dickler M, Rugo H, Caravelli J, Brogi E, Sachs D, Panageas K, Flores S, Moasser M, Norton L, Hudis C. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). In: Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004; 2001.Google Scholar
  72. 72.
    Beeram M, De Bono J, Patnaik A, Mita A, Chu S, Mita M, O'Rourke P, Takimoto CH, Tolcher AW, Rowinsky EK. Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (Erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors. In: San Antonio Breast Cancer Symposium. Abstract No. 2034. 2005.Google Scholar
  73. 73.
    Burris HA, 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23(23):5305–13.PubMedCrossRefGoogle Scholar
  74. 74.
    Gomez H, Chavez M, Doval D, Chow L, Wood B, Berger M, Sledge GW. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Abstract No: 3046. In: 2005 ASCO Annual Meeting.Google Scholar
  75. 75.
    Blackwell K, Kaplan E, Franco S, Marcom P, Maleski J, Sorensen M, Berger MS. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. In: Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004; 3006.Google Scholar
  76. 76.
    Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11(9):3369–76.PubMedCrossRefGoogle Scholar
  77. 77.
    Geyer CE, Forster JK, Cameron D, Chan S, Pienkowski T, Romieu CG, Jagiello-Gruszweld A, Crown J, Kaufman B, Chan A. Scientific Special Session: Lapatinib in Tratuzumab Resistant Breast Cancer. In: 2006 ASCO Annual Meeting.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Samuel K. Chan
    • 1
    • 2
  • Mark E. Hill
    • 2
  • William J. Gullick
    • 1
    Email author
  1. 1.Cancer Biology LaboratoryResearch School of Biosciences, University of KentCanterburyUK
  2. 2.Kent Oncology CentreMaidstoneUK

Personalised recommendations